Aim: To evaluate the efficacy and safety of mealtime or post-meal fast-acting insulin aspart (faster aspart) vs mealtime insulin aspart (IAsp), both in combination with insulin degludec, in participants with type 1 diabetes (T1D).
now being complemented by emergence of ultra-fast-acting mealtime insulins. These agents incorporate modifications to insulin formulations to accelerate absorption and thereby improve insulin timeaction and PPG-lowering profiles. [8] [9] [10] [11] [12] Fast-acting insulin aspart (faster aspart) is a faster-acting mealtime insulin with a more rapid rate of absorption into the bloodstream and greater early-glucose-lowering effect than conventional insulin aspart (IAsp). 13 Faster aspart has been approved for use by the US Food and Drug Administration (FDA) and the European Medicines Agency (EMA) as treatment for diabetes in adults.
In the onset 1 trial, the efficacy and safety of faster aspart were evaluated as part of a basal-bolus regimen with insulin detemir (detemir) in participants with T1D. 14 15 Faster aspart administered 20 minutes after the start of the meal was noninferior (0.4% margin) to mealtime IAsp regarding change in HbA1c after 26 weeks of treatment. 14 To date, no studies comparing faster aspart with IAsp in a basalbolus regimen with ultra-long-acting basal insulins are available. The onset 8 study is similar in design to the onset 1 study, and aims to evaluate the efficacy and safety of faster aspart in conjunction with degludec in participants with T1D. The onset 8 study was designed to quantify a population average effect, irrespective of adherence to randomized treatment and ancillary therapy use. The primary objective was to estimate the effect based on difference in HbA1c from baseline to 26 weeks under these circumstances. As it can sometimes be challenging to administer bolus insulin before a meal, a post-meal faster aspart arm (administration within 20 minutes after start of the meal) was also included to further evaluate the option of administering faster aspart after a meal when needed.
| RESEARCH DESIGN AND METHODS

| Trial design
In this Phase 3b, multicentre, active-controlled, randomized, parallelgroup study (ClinicalTrials.gov: NCT02500706), mealtime faster aspart was compared with mealtime IAsp, both double-blind, in adults with T1D over 26 weeks ( Figure S1 in File S1). In a third, open-label treatment arm, participants received post-meal faster aspart (Figure S1 in File S1). Faster aspart and IAsp were delivered in a basal-bolus regimen in conjunction with once-daily degludec. The trial was conducted in accordance with the Declaration of Helsinki and International Conference on Harmonization of Good Clinical Practice. The study was conducted at 146 centres in 12 countries/regions (Appendix S1 in File S1). Follow-up assessment took place 7 and 30 days after end of treatment.
| Study population
Adults (≥18 years of age; ≥20 years in Japan and Taiwan) with T1D were eligible for inclusion if they had received a basal-bolus insulin regimen for at least 12 months before screening, including a basal insulin analogue for at least 4 months before screening. Eligibility also required HbA1c to be 7.0% to 9.5% (53-80 mmol/mol) and BMI to be 35.0 kg/m 2 or less.
Key exclusion criteria included: treatment with any antidiabetic or obesity medication, other than listed inclusion criteria, within 3 months before screening; any anticipated change in concomitant medications known to affect glucose metabolism persisting beyond 2 weeks of study inclusion; myocardial infarction, stroke or hospitalization for unstable angina and/or transient ischaemic attack within 180 days before screening; use of continuous glucose monitoring;
inadequately-treated hypertension (≥Class 2) or clinically significant hepatic or renal insufficiency (full criteria in Appendix S1, File S1).
| Interventions
| Basal titration during the trial
After a two-week screening period, an eight-week run-in period allowed for basal insulin titration, and participants switched from their existing basal insulin analogue to degludec (100 U/mL, 3-mL pen injector) at the start, based on protocol-specified guidelines (Table S1 in File S1). During the run-in period, the investigator titrated degludec on a weekly basis to the pre-breakfast glycaemic target of 4.0 to 5.0 mmol/L in accordance with titration guidelines (Table S2 in File S1). Further adjustment of degludec during the treatment period was performed at the investigator's discretion.
| Bolus dosing during the trial
At the start of the run-in period, participants switched from their previous bolus insulin to IAsp (all bolus insulins supplied as 100 U/mL, 3-mL pen injector) on a unit-for-unit basis. IAsp dose was not adjusted during the run-in period unless considered necessary by the investigator. At the end of the run-in period, participants with HbA1c at 9.5% (80 mmol/mol) or less were randomized 1:1:1 to receive double-blind mealtime IAsp, double-blind mealtime faster aspart or open-label post-meal faster aspart. Mealtime insulins were injected 0 to 2 minutes before a meal, while post-meal faster aspart was injected at the end of a meal, no later than 20 minutes after the start of the meal.
During the 26-week treatment period, bolus insulin was titrated to achieve a glycaemic target of pre-prandial and bedtime plasma glucose (PG) between 4.0 and 6.0 mmol/L. Participants who were considered proficient in carbohydrate counting continued using this method for bolus adjustment during the treatment period, while all other participants used a predefined bolus-dosing algorithm ( Table S3 in File S1).
Meal carbohydrate content and pre-prandial BG values were used to determine bolus-insulin doses for participants, based on flexible dosing principles. Doses were calculated several times daily by each participant based on the insulin:carbohydrate ratio and insulin correction factor. Weekly review of the ratio and correction factor was performed by the investigator, based on each participant's self-measured blood glucose (SMBG) values. In the event of hypoglycaemia, the dose could be reduced at the investigator's discretion.
| Self-measured blood glucose (SMBG)
Participants were supplied with a BG meter (Abbott Precision Neo or Precision; Abbott Laboratories, Chicago, Illinois) and were instructed to record the date, time and value of all SMBG measurements relating to 4-, 7-and 9-point profiles and hypoglycaemic episodes. The 4-point profiles, before each main meal (breakfast, lunch, evening meal) and at bedtime, were recorded daily for insulin titration purposes. The 7-9-7-point profiles, before and 60 minutes after each main meal, at bedtime, at 4:00 AM (9-point only) and before breakfast the following day (9-point only), were recorded on three consecutive days (7-point profiles for Days 1 and 3, a 9-point profile on Day 2) before scheduled clinic visits at Weeks 0, 12 and 26.
| Standardized meal test
Participants were required to attend the standardized meal test with a fasting SMBG of 4.0 to 8.8 mmoL/L. Before randomization at Week 0 (baseline), a bolus dose of IAsp was administered (0.1 U/kg, calculated by investigator), followed by a standardized mixed liquid-meal test (78 g carbohydrate consumed within 12 minutes). Blood samples were taken immediately before the meal and after 30 minutes, 1, 2, (Table S4 in File S1).
| Secondary endpoints
Supportive secondary safety endpoints were: treatmentemergent adverse events (TEAEs), treatment-emergent injection site reactions; treatment-emergent hypoglycaemic episodes (overall and after meal [1, 1-2, 2-3 and 3-4 hour timepoints]); physical examination; vital signs; electrocardiogram; fundoscopy; laboratory parameters; anti-IAsp antibody development (specific and crossreacting with human insulin); and body weight. (See Appendix S1, in File S1 for TEAEs and treatment-emergent hypoglycaemia definitions).
| Statistical methods
All statistical analyses were prespecified. Efficacy endpoints were summarized using the full analysis set, and results are presented based on data from all randomized participants for the entire trial period, which includes data collected after participants prematurely discontinued treatment (in-trial observation period). Safety endpoints were summarized using the safety analysis set (participants receiving ≥ 1 dose of IAsp or faster aspart). Statistical analysis of primary and secondary confirmatory endpoints followed a stepwise hierarchical procedure, which was discontinued after step 4 ( Figure S2 and Table S5 in File S1). Non-inferiority, the primary endpoint, was confirmed if the upper boundary of the two-sided 95% CI was 0.4% or less. Two-sided P-values are presented unless stated otherwise. culation and further details on statistical methods for primary and secondary endpoints are provided in Appendix S1, File S1).
| RESULTS
| Trial participants
In total, 1025 participants were randomized to mealtime faster aspart (n = 342), IAsp (n = 342), or post-meal faster aspart (n = 341), all exposed to their respective study medications, among whom 1007 participants (98.2%) completed the trial, while 999 participants (97.5%), similarly distributed across treatment arms, completed the 26-week treatment period without premature discontinuation of randomized treatment ( Figure S3 in File S1). The most common reason for withdrawal from the trial was "withdrawal by subject" (four participants each in the mealtime faster aspart and IAsp arms, six in the postmeal faster aspart arm). Seven, nine and ten participants in the mealtime faster aspart, post-meal faster aspart and mealtime IAsp arms, respectively, prematurely discontinued randomized treatment.
Baseline demographics and disease characteristics were similar between the three treatment arms (Table 1 ).
| Efficacy
| Change in HbA1c
During the run-in period, observed mean HbA1c was reduced from 8.1%
(65 mmol/mol) to 7.5% (58 mmol/mol) in participants subsequently randomized to mealtime faster aspart, from 8.0% (63 mmol/mol) to 7.4% (57 mmol/mol) in those randomized to mealtime IAsp, and from 8.1%
(65 mmol/mol) to 7.4% (57 mmol/mol) in those randomized to post-meal faster aspart (Figure 1) . At the end of the 26-week treatment period, mean HbA1c was 7.3% (57 mmol/mol), 7.3% (56 mmol/mol) and 7.4% Table S5 in File S1).
The odds of achieving HbA1c less than 7.0% (53 mmol/mol) were not statistically significantly different between mealtime faster aspart and IAsp, or between post-meal faster aspart and mealtime IAsp (Table S6 in File S1). 
| Meal test
| Self-measured blood glucose
Observed mean 9-point SMBG profiles at baseline and after 26 weeks of treatment were similar between groups ( Figure S4 in File S1), and there were no statistically significant differences in mean SMBG for mealtime or post-meal comparisons ( Table S6 in File S1). Regarding change from baseline in 1-hour PPG increment (based on SMBG), (Table S6 in File S1). No clinically significant differences were seen in lipid-lipoprotein profiles.
| Other secondary endpoints
| Safety
Results concerning hypoglycaemia are presented in Table 2 . No statistically significant differences were observed between the faster aspart No clinically significant differences between treatment groups were observed regarding percentage of participants who reported TEAEs and the overall rate of TEAEs, which was similar between the three treatment arms (Table S7 in File S1); regarding injection-site and allergic reactions, which were low in number and evenly distributed across the three treatment arms (Table S7 in File S1); and regarding vital signs and the results of physical examination and safety laboratory assessments. Additional details are shown in Appendix S1, File S1.
During the trial, mean and median daily bolus insulin doses increased by similar amounts in all three treatment groups (Table S7 in File S1), and the basal/bolus ratio 26 weeks post randomization changed to a higher proportion of bolus compared with basal insulin across the three treatment arms (Table S8 in File S1).
| DISCUSSION
The results of this study confirm that both mealtime and post-meal faster aspart, in combination with degludec, were non-inferior to mealtime IAsp regarding change in HbA1c from baseline to 26 weeks in individuals with T1D. Furthermore, mealtime faster aspart was effective in reducing PPG excursions, and superiority to IAsp in 1-hour PPG increment, following a standardized meal test, was confirmed. Mean SMBG-derived 1-hour PPG increments also showed a trend towards improved PPG control, with mealtime faster aspart conferring a significantly lower 1-hour PPG increment than IAsp at breakfast and also when averaged over all meals. Furthermore, significantly more participants who received mealtime faster aspart achieved a 1-hour PPG target less than 7.8 mmol/L, based on SMBG, compared with those who received IAsp. Change in body weight was less than 2 kg in all three treatment arms, which may be expected given that participants were already on a basal-bolus regimen at baseline.
The improved PPG findings reported in the present study, from both meal test and SMBG, are consistent with general findings across the faster aspart clinical trial programme. 14, 15, 17, 18 Furthermore, the results here specifically support the results of the onset 1 study, in which once-or twice-daily detemir in conjunction with mealtime or post-meal faster aspart was compared with the same basal regimen and mealtime IAsp. 14 In the onset 1 study, however, there was a statistically significant difference in HbA1c change after 26 weeks between mealtime faster aspart and IAsp, unlike in the present study.
Despite the reported improvements in PPG and the similar patient populations in both studies, it is unclear why a greater difference in change in HbA1c between mealtime faster aspart and IAsp was not observed in the present study. There was also a discrepancy between the two studies in the incidence of meal-related hypoglycaemia at 1 hour after the start of a main meal. In the present study, there was no significant difference between mealtime faster aspart and IAsp regarding the rate of severe or BG-confirmed hypoglycaemic episodes 1 hour after a main meal, whereas a statistically significant difference in favour of IAsp was recorded in the onset 1 study (rate ratio: faster aspart/IAsp 1.48 [95%CI, 1.11; 1.96]; P = 0.0073). 14 Conversely, there was a significant reduction in meal-related hypoglycaemia in favour of mealtime faster aspart 3 to 4 hours after a main meal in the present study. These differences are probably related to the reported left shift of the concentration-time curve for faster aspart relative to IAsp, reflective of the faster onset and offset of action of faster aspart. 13 While mealtime dosing of insulin is appropriate for many patients with diabetes, there are situations in which the increased flexibility of post-meal dosing may be advantageous. During social or other occasions, for example, the timing and/or carbohydrate content of a meal may be unpredictable. Furthermore, elderly or hospitalized patients, in whom lack of appetite and nausea are common, may also benefit from post-meal dosing, as might patients who have forgotten an injection, or are anxious about severe hypoglycaemia. 19, 20 Although post-meal dosing cannot be recommended, the results of the present study suggest that post-meal dosing of faster aspart may be considered in patients who need it.
This study employed once-daily degludec as the basal insulin.
Degludec is associated with tolerability and overall glycaemic control similar to other long-acting insulin analogues, with the benefit of a reduced rate of overall symptomatic hypoglycaemic and severe hypoglycaemic events, [21] [22] [23] which may have contributed to the lower rates of hypoglycaemia observed here compared with observations during the onset 1 study. 14 
